2. Academic Validation
  3. MYSM1 Represses Innate Immunity and Autoimmunity through Suppressing the cGAS-STING Pathway

MYSM1 Represses Innate Immunity and Autoimmunity through Suppressing the cGAS-STING Pathway

  • Cell Rep. 2020 Oct 20;33(3):108297. doi: 10.1016/j.celrep.2020.108297.
Mingfu Tian 1,  Weiyong Liu 1,  Qi Zhang 1,  Yuqing Huang 1,  Wen Li 1,  Wenbiao Wang 2,  Peiyi Zhao 1,  Shanyu Huang 1,  Yunting Song 1,  Muhammad Adnan Shereen 1,  Mengying Qin 1,  Yingle Liu 1,  Kailang Wu 3,  Jianguo Wu 4
Affiliations

Affiliations

  • 1 State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
  • 2 Guangzhou Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China.
  • 3 State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China. Electronic address: [email protected].
  • 4 State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China; Guangzhou Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China. Electronic address: [email protected].
PMID: 33086059 DOI: 10.1016/j.celrep.2020.108297
Abstract

The immune system is not only required for preventing threats exerted by pathogens but also essential for developing immune tolerance to avoid tissue damage. This study identifies a distinct mechanism by which MYSM1 suppresses innate immunity and autoimmunity. The expression of MYSM1 is induced upon DNA virus Infection and by intracellular DNA stimulation. MYSM1 subsequently interacts with STING and cleaves STING K63-linked ubiquitination to suppress cGAS-STING signaling. Notably, Mysm1-deficient mice exhibit a hyper-inflammatory response, acute tissue damage, and high mortality upon virus Infection. Moreover, in the PBMCs of patients with systemic lupus erythematosus (SLE), MYSM1 production decreases, while type I interferons and pro-inflammatory cytokine expressions increase. Importantly, MYSM1 treatment represses the production of IFNs and pro-inflammatory cytokines in the PBMCs of SLE patients. Thus, MYSM1 is a critical repressor of innate immunity and autoimmunity and is thus a potential therapeutic agent for infectious, inflammatory, and autoimmune diseases.

Keywords

ADV; HSV-1; MYSM1; Myb-like; SLE; STING; SWIRM; adenovirus; and MPN domains 1 protein; autoimmune disease; autoimmunity; cGAS; cyclic GMP-AMP synthase; herpes simplex virus type 1; innate immunity; pro-inflammatory cytokines; stimulator of interferon genes; systemic lupus erythematosus; type I interferon.

Figures